Repligen's top-line recovery is gaining traction, with revenue up 11.9% year-over-year to $204.1M in 2026Q2, marking the fourth consecutive quarter of accelerating growth and signaling a potential end to the bioprocessing destocking cycle. However, profitabili...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 11.9% year-over-year in 2026Q2, but operating margin remains compressed at 5.8% due to sticky SG&A costs of $76.6M, well below the 20%+ levels seen historically.
Repligen is a specialized life sciences company with a highly differentiated product portfolio critical to biologic drug manufacturing.
Repligen reported financial results for Q1 2026, indicating continued growth and operational success.
MarketBeat offers access to Repligen's complete SEC filing history, including annual and quarterly reports, providing transparency for investors.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | $0.54+20.8% vs $0.45 | $204M+1.3% vs $202M |
Q2 2026 May 5, 2026 | $0.48+26.3% vs $0.38 | $194M+1.1% vs $192M |
Q1 2026 Feb 24, 2026 | $0.49+11.4% vs $0.44 | $198M+2.6% vs $193M |
Q4 2025 Oct 28, 2025 | $0.46+9.5% vs $0.42 | $189M+3.7% vs $182M |
Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,863 shares of the biotechnology company's stock after acquiring an additional 3,803 shares during
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Benchmark RGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Repligen Corporation (RGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $184.53 | $10.41B | 214.57 | 16.36% | 6.62% | 2.4% | — | |
| $19.52 | $1.86B | -1.81 | 1% | -3.18% | -15.53% | — | |
| $390.79 | $55.97B | -257.10 | 35.9% | -7.11% | -11.73% | — | |
| $34.09 | $1.57B | -27.94 | 3.55% | -20.02% | -7.56% | — | |
| $59.67 | $9.08B | -397.80 | 2.08% | -2.03% | -2.87% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — |
Repligen Corporation (RGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Repligen Corporation (RGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
Jul 22, 2026·SEC
May 15, 2026·SEC
Get notified when RGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Repligen Corporation (RGEN) stock FAQ — growth, dividends, profitability & financials explained
Repligen Corporation (RGEN) reported $785.1M in revenue for fiscal year 2025. This represents a 7103% increase from $10.9M in 1996.
Repligen Corporation (RGEN) grew revenue by 16.4% over the past year. This is strong growth.
Yes, Repligen Corporation (RGEN) is profitable, generating $41.5M in net income for fiscal year 2025 (6.6% net margin).
Repligen Corporation (RGEN) has a return on equity (ROE) of 2.4%. This is below average, suggesting room for improvement.
Repligen Corporation (RGEN) generated $110.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
